Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.66 is 289% below its 5-year average of -1.20, near the low end of its 5-year range (-4.66–-0.50).
121.90% below its 12-month average of -2.10.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.10.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-4.66
EARNINGS PER SHARE (EPS) AVG TTM
-2.10
EARNINGS PER SHARE (EPS) AVG 3Y
-1.50
EARNINGS PER SHARE (EPS) AVG 5Y
-1.20
EARNINGS PER SHARE (EPS) AVG 10Y
-1.21
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-121.90%
CURRENT VS 3Y AVG
-211.19%
CURRENT VS 5Y AVG
-288.87%
CURRENT VS 10Y AVG
-285.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Viking Therapeutics, Inc.
Market Cap
$3.31B
Earnings Per Share (EPS)
-4.66
TTM Avg
-2.10
3Y Avg
-1.50
5Y Avg
-1.20
Market Cap
$3.32B
Earnings Per Share (EPS)
N/A
TTM Avg
-87.94
3Y Avg
-87.94
5Y Avg
-87.94
Market Cap
$3.38B
Earnings Per Share (EPS)
2.22
TTM Avg
1.84
3Y Avg
0.49
5Y Avg
-0.14
Market Cap
$3.21B
Earnings Per Share (EPS)
-1.09
TTM Avg
-2.33
3Y Avg
-2.95
5Y Avg
-2.30
Market Cap
$3.44B
Earnings Per Share (EPS)
-1.17
TTM Avg
-1.00
3Y Avg
-1.15
5Y Avg
-1.50
Market Cap
$3.45B
Earnings Per Share (EPS)
-1.94
TTM Avg
-2.32
3Y Avg
-2.00
5Y Avg
-1.79
Market Cap
$3.47B
Earnings Per Share (EPS)
-4.29
TTM Avg
-3.30
3Y Avg
-2.99
5Y Avg
-2.52
Market Cap
$3.52B
Earnings Per Share (EPS)
-4.74
TTM Avg
-3.69
3Y Avg
-3.04
5Y Avg
-2.46
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | $3.31B | -4.66 | -2.10 | -1.50 | -1.20 |
| CareDx, Inc (CDNA)vs › | $3.34B | 2.07 | 0.30 | -1.10 | -0.90 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.32B | N/A | -87.94 | -87.94 | -87.94 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 2.22 | 1.84 | 0.49 | -0.14 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.21B | -1.09 | -2.33 | -2.95 | -2.30 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -1.17 | -1.00 | -1.15 | -1.50 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.45B | -1.94 | -2.32 | -2.00 | -1.79 |
| Celcuity Inc. (CELC)vs › | $3.47B | -4.29 | -3.30 | -2.99 | -2.52 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.52B | -4.74 | -3.69 | -3.04 | -2.46 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | -0.43 | -2.51 | -3.24 | -3.00 |
Trailing EPS (TTM)
$-4.66
Forward EPS (Est.)
$-4.61
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.19 |
| 2024-12-31 | -1.01 |
| 2023-12-31 | -0.91 |
| 2022-12-31 | -0.88 |
| 2021-12-31 | -0.70 |
| 2020-12-31 | -0.50 |
| 2019-12-31 | -0.36 |
| 2018-12-31 | -0.38 |
| 2017-12-31 | -0.79 |
| 2016-12-31 | -0.90 |
| 2015-12-31 | -3.68 |
| 2014-12-31 | -5.08 |
| 2013-12-31 | -0.03 |
| 2012-12-31 | -0.30 |
